Enanta Pharmaceuticals Inc. (NASDAQ: ENTA) stock closed at 40.07 per share at the end of the most recent trading day (a 1.19% change compared to the prior day closing price) with a volume of 142.40K shares and market capitalization of 836.90M. Is a component of indices and it is traded on NASDAQ exchange. The company belongs in the Biotechnology industry, Healthcare sector and employs 141 people. Enanta Pharmaceuticals Inc. CEO is Jay R. Luly.

The one-year performance of Enanta Pharmaceuticals Inc. stock is -41.57%, while year-to-date (YTD) performance is -13.87%. ENTA stock has a five-year performance of -50.34%. Its 52-week range is between 37.59 and 79.495, which gives ENTA stock a 52-week price range ratio of 5.92%

Enanta Pharmaceuticals Inc. currently has a PE ratio of -8.40, a price-to-book (PB) ratio of 3.22, a price-to-sale (PS) ratio of 16.77, a price to cashflow ratio of 154.60, a PEG ratio of 2.32, a ROA of -32.59%, a ROC of -30.48% and a ROE of -36.91%. The company’s profit margin is -81.96%, its EBITDA margin is -142.50%, and its revenue ttm is $58.51 Million , which makes it $2.81 revenue per share.

Of the last four earnings reports from Enanta Pharmaceuticals Inc., there were 2 positive earnings surprise and 2 negative earnings surprise. The company has EPS estimate of $-1.91 for the next earnings report. Enanta Pharmaceuticals Inc.’s next earnings report date is 08th May 2023.

The consensus rating of Wall Street analysts for Enanta Pharmaceuticals Inc. is Moderate Buy (1.89), with a target price of $72.1, which is +79.94% compared to the current price. The earnings rating for Enanta Pharmaceuticals Inc. stock is Strong Buy (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).

Enanta Pharmaceuticals Inc. has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.

Enanta Pharmaceuticals Inc. has a Sell technical analysis rating based on Technical Indicators (ADX : 7.17, ATR14 : 2.09, CCI20 : -125.89, Chaikin Money Flow : -0.29, MACD : -2.44, Money Flow Index : 31.86, ROC : -15.05, RSI : 23.53, STOCH (14,3) : 13.24, STOCH RSI : 0.42, UO : 33.24, Williams %R : -86.76), Simple Moving Averages and Exponential Moving Averages.

Aggregated Insider Trades of Enanta Pharmaceuticals Inc. in the last 12-months were: Jay R. Luly (Option Excercise at a value of $790 678), Jay R. Luly (Sold 27 912 shares of value $1 260 628 ), Nathalie Adda (Option Excercise at a value of $3 386 446), Nathalie Adda (Sold 83 344 shares of value $5 967 688 ), Paul J. Mellett (Option Excercise at a value of $139 652), Paul J. Mellett (Sold 5 000 shares of value $268 816 )